Increasing Clinical Trial Activity Boosting Growth in the Autoimmune Gastrointestinal Dysmotility Market
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Autoimmune Gastrointestinal Dysmotility Market During The Forecast Period 2026–2030?
The autoimmune gastrointestinal dysmotility market size has shown robust growth over recent years. It is anticipated to expand from $1.82 billion in 2025 to $1.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to factors such as an increase in autoimmune disease diagnoses, the prevalence of gastroparesis, the expansion of hospital gastroenterology departments, the use of immunosuppressive drugs, and greater awareness of rare diseases.
The autoimmune gastrointestinal dysmotility market is anticipated to show considerable growth in the coming years, with its value expected to reach $2.63 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.2%. The expansion over the forecast period is attributable to improvements in early diagnostics, the emergence of personalized treatment approaches, increased demand for long-term care, the adoption of home-based nutrition therapy, and the broadening of autoimmune research. Noteworthy trends during this period include a heightened recognition of rare gastrointestinal disorders, an increase in the use of immunosuppressive treatments, the expansion of nutritional and dietary management strategies, the rising adoption of multidisciplinary care approaches, and an emphasis on long-term symptom management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
Which Major Factors Are Driving The Expansion Of The Autoimmune Gastrointestinal Dysmotility Market?
The expansion in the volume of clinical trials is projected to fuel the advancement of the autoimmune gastrointestinal dysmotility market moving forward. Clinical trials are research endeavors designed to assess the safety, efficacy, and optimal application of medical treatments, including various drugs, biologics, devices, and therapeutic protocols, in human participants, with the goal of expanding medical understanding and enhancing patient care. This growth in clinical trials primarily stems from broadened regulatory requirements for trial registration, increased financial commitment to pharmaceutical research and development, and the swift pace of breakthroughs in novel treatment methods like immunotherapies and biologics, which target autoimmune conditions affecting gastrointestinal motility. Clinical trials focused on autoimmune gastrointestinal dysmotility contribute to improving treatment options by systematically evaluating new immunosuppressive agents, prokinetic drugs, and biologics, identifying the most effective treatment regimens for managing gastrointestinal motility disorders, and laying down evidence-based foundations that facilitate regulatory approvals and the integration of groundbreaking therapies for autoimmune-driven gastrointestinal dysfunction into clinical practice. For example, by November 2025, according to ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, the total count of registered clinical studies reached 477,203 by the close of 2023 (including 437,493 cumulative and 39,710 new registrations) and further grew to 520,877 by the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), indicating a 9.1% year-on-year rise in overall registered studies. Consequently, the increasing number of clinical trials is stimulating the growth of the autoimmune gastrointestinal dysmotility market.
What Market Segments Are Evaluated Within The Autoimmune Gastrointestinal Dysmotility Market?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs)
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Who Are The Top Market Participants Influencing The Autoimmune Gastrointestinal Dysmotility Market?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Read the full autoimmune gastrointestinal dysmotility market report here:
Which Region Currently Holds The Largest Share Of The Autoimmune Gastrointestinal Dysmotility Market?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Autoimmune Gastrointestinal Dysmotility Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp
Browse Through More Reports Similar to the Global Autoimmune Gastrointestinal Dysmotility Market 2026, By The Business Research Company
Autoimmune Disease Diagnosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Veterinary Autoimmune Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
